Q: Hey. So I'm in third year, and I'll be a student, and I have a-- I'm presently studying BSc. I'm studying a lesson, communicable diseases and epidemiology. We actually have to answer questions for exam in order, like for each disease, we have to write epidemiology, clinical features, treatment, prevention, complications. So can you like give me a pro forma that I can use for all the questions? Actually, not a pro forma, but, um... Uh, can you actually give me... You can give me the performer. Uh, I will send you the performer. I will give you the performer. Just, uh, give me any disease that I want according to that performer. Okay? Okay. A: I can see your proforma clearly from the images! It's a 3-page "Communicable Disease Epidemiology" quick reference for 3rd Year MBBS/PSM covering 6 sections: 1. Epidemiology Agent, Host, Environmental factors + Transmission + Descriptive Epi 2. Clinical Features Stages + Cardinal features + Severity classification 3. Diagnosis Lab investigations + WHO/IDSP case definitions 4. Treatment Supportive + Specific + Isolation & Notification 5. Complications System-wise, acute, long-term 6. Prevention & Control Primary/Secondary/Tertiary + Outbreak control + National Programs Got it perfectly. Now just tell me which disease you want, and I'll fill in every section of this proforma with exam-ready content. Which disease do you want to start with? Q: Polio A: Searching sources... A: I now have enough to write a complete, exam-ready answer. Here it is: --- POLIOMYELITIS Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM --- 1. EPIDEMIOLOGY Agent Factors Epidemiological Triad Parameter Details ------ Causative agent Poliovirus - RNA virus, Family Picornaviridae, Genus Enterovirus Types 3 serotypes: Type 1 most common, most paralytic, Type 2 eradicated 2015, Type 3 eradicated 2019 Source of infection Human case or carrier no animal reservoir - anthroponosis Reservoir Human only Infective material Faeces primary, oropharyngeal secretions Infectivity Highly infectious; subclinical cases are the main source of spread Pathogenicity Low 2% develop paralysis Antigenicity Strong - immunity is type-specific and lifelong after infection or vaccination Host Factors Parameter Details ------ Age group Mainly children under 5 years "Infantile Paralysis" Sex Males slightly more susceptible to paralytic form Immunity Type-specific; herd immunity threshold 80-85% Risk factors Unvaccinated status, pregnancy, tonsillectomy increases bulbar polio risk, strenuous exercise during prodrome, IM injections provocation polio Environmental Factors - Season/Climate: Temperate countries - summer/autumn peak; tropical countries - year-round - Geography: Endemic in Afghanistan and Pakistan wild poliovirus type 1 remains; vaccine-derived poliovirus VDPV outbreaks in Africa - Socioeconomic: Poor sanitation, overcrowding, unsafe water supply, poverty favor spread Transmission Parameter Details ------ Mode Faecal-oral primary; droplet/respiratory secondary Vehicle Contaminated water, food, hands Portal of entry GI tract oropharynx and intestine Incubation period 4-35 days; usually 7-14 days for paralytic disease Period of communicability Virus shed in throat for 1 week and in faeces for 3-6 weeks; most infectious in the week before and after symptom onset Descriptive Epidemiology - Global burden: Peak 350,000 cases in 125 countries in 1988; reduced 99% by vaccination. Wild-type cases: 12 in 2023 all type 1, all from Pakistan/Afghanistan. VDPV cases remain a challenge 526 cases in 2023, mainly cVDPV2 - Indian scenario: India certified polio-free by WHO on 27 March 2014. Last wild poliovirus case: 13 January 2011 Howrah, West Bengal. Under Pulse Polio Programme PPP since 1995-96; notifiable disease under IDSP - Epidemic pattern: Endemic in polio-endemic countries; epidemics in under-vaccinated populations; global campaign under Global Polio Eradication Initiative GPEI --- 2. CLINICAL FEATURES Stages of Disease Stage Features ------ Incubation period 7-14 days range 4-35 days Prodromal / Minor illness stage Fever, malaise, headache, sore throat, vomiting, abdominal pain 2-3 days Preparalytic stage Return of fever biphasic/dromedary fever, severe myalgia, meningism, muscle tenderness, spasm Paralytic stage Fastigium Flaccid paralysis - develops rapidly over 1-3 days; maximum within a few days Convalescence Recovery may occur for up to 6 months; paralysis after 6 months is permanent Cardinal / Pathognomonic Features - Asymmetric flaccid paralysis WITHOUT sensory loss - hallmark finding - Biphasic dromedary fever - fever, apparent recovery, then return of fever with paralysis - Trendelenburg gait gluteal muscle weakness - Tripod sign / Head drop sign - due to neck muscle weakness - Positive "Hoyne's sign" - inability to flex neck - Loss of superficial and deep reflexes in affected limbs Clinical Types / Grades / Severity Classification Type Features Frequency --------- Inapparent / Subclinical No symptoms 90-95% Abortive poliomyelitis Minor febrile illness, no CNS involvement, recovery in 2-3 days 4-8% Non-paralytic Aseptic meningitis Meningeal signs + fever, stiff neck/back; no paralysis; full recovery 1% Paralytic poliomyelitis Flaccid paralysis; sub-types below 2% Sub-types of Paralytic Polio: - Spinal type most common - anterior horn cell destruction; lower limb upper limb - Bulbar type - cranial nerve nuclei affected; respiratory and swallowing muscles involved; MOST DANGEROUS ⭐ - Bulbospinal type - combined; worst prognosis --- 3. DIAGNOSIS Lab Investigations Investigation Details ------ Clinical diagnosis Acute flaccid paralysis AFP in child 15 years with fever at onset Routine labs CBC leukocytosis, CSF increased cells - lymphocytes, normal glucose, slightly raised protein Specific tests Stool culture for poliovirus 2 samples ≥24 hrs apart, within 14 days of onset - gold standard; throat swab culture; CSF culture; RT-PCR Gold standard Stool virus isolation culture - poliovirus isolated and typed Serology 4-fold rise in neutralizing antibody titres Case Definition WHO / IDSP Definition Criteria ------ Suspected case AFP Any child 15 years with acute flaccid paralysis, OR any person of any age with paralytic illness if polio is suspected Probable case AFP + compatible epidemiological and clinical picture Confirmed case AFP + poliovirus isolated from stool specimen Compatible case AFP without adequate stool specimens and residual paralysis or death Notifiable? YES - notifiable under IDSP; any AFP case must be reported within 24 hours to CMO --- 4. TREATMENT General / Supportive Care - Complete bed rest during acute febrile phase strenuous activity worsens paralysis - Hydration and nutrition support - Antipyretics and analgesics for fever and pain - Moist hot packs to relieve muscle spasm - Careful positioning to prevent deformities - Monitor respiratory function especially in bulbar type - may need mechanical ventilation Specific Treatment Parameter Details ------ Drug of choice No specific antiviral treatment available Supportive IV immunoglobulin in immunocompromised patients Respiratory support Mechanical ventilation / iron lung for bulbar/respiratory involvement ⭐ Rehabilitation Physiotherapy, orthotic devices, corrective surgery in convalescence Contraindicated Glucocorticoids steroids worsen outcome; IM injections during febrile illness provocation polio Isolation & Notification - Isolation type: Enteric precautions faecal-oral route - Duration: Until cultures are negative at least 6 weeks - Notification: Compulsory notification to CMO within 24 hours; any AFP case is notifiable under IDSP; International Health Regulations IHR 2005 - polio is a PHEIC-level concern --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ Immediate / Acute ⭐ Respiratory failure bulbar polio - MOST DANGEROUS; acute myocarditis Musculoskeletal Flaccid paralysis, muscle wasting, joint deformities equinus foot, claw foot, limb shortening Neurological Bulbar involvement - dysphagia, dysarthria, facial weakness Long-term sequelae ⭐ Post-Polio Syndrome PPS - new onset weakness, fatigue, pain 25-40 years after original illness Psychological Depression, social isolation due to disability Complications of treatment Pressure sores from immobility; respiratory infections ⭐ Most dangerous complication: Respiratory failure in bulbar polio ⭐ Important long-term: Post-Polio Syndrome PPS --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Health education about vaccination importance - Safe water supply and proper sewage disposal - Food hygiene and hand-washing - Nutritional improvement and improvement in living standards Primary Prevention - Specific Protection Immunization: Feature OPV Oral Polio Vaccine / Sabin IPV Inactivated Polio Vaccine / Salk --------- Type Live attenuated Killed / Inactivated Route Oral 2 drops Intramuscular injection Immunity Humoral + intestinal mucosal IgA Humoral only IgG Herd immunity YES - virus shed, spreads immunity No shedding Risk VAPP Vaccine-Associated Paralytic Polio 1 in 2.7 million None Cold chain Requires -20°C Requires 2-8°C India's Schedule Universal Immunization Programme: - IPV: 6 weeks, 14 weeks introduced 2015 - bOPV bivalent OPV - types 1 & 3: 6, 10, 14 weeks + booster at 16-24 months - Pulse Polio Programme: Supplementary OPV on National Immunization Days NIDs and Sub-NIDs Chemoprophylaxis: OPV given to all children 5 years during outbreak Vector control: Not applicable no vector Personal protection: Hand hygiene, safe water use Secondary Prevention - Early Diagnosis + Prompt Treatment - Active AFP Acute Flaccid Paralysis surveillance - WHO standard: ≥1 AFP case per 100,000 children 15 years/year with adequate stool specimens = good surveillance - Passive surveillance through IDSP - Contact tracing - all contacts vaccinated immediately with OPV - Sentinel surveillance Tertiary Prevention - Rehabilitation - Physiotherapy and occupational therapy to maximize function - Orthotics and assistive devices callipers, crutches - Corrective surgery tendon transfers, arthrodesis for deformities - Social and vocational rehabilitation - Long-term follow-up for Post-Polio Syndrome Control Measures During an Outbreak - Case isolation: Enteric precautions - Contact tracing: All household and community contacts vaccinated with OPV within 72 hours - Disinfection: Concurrent disinfection of faeces, urine, vomit; terminal disinfection - Mop-up vaccination: Door-to-door OPV in the affected area - Epidemiological investigation: Attack rate, identify source, spot map, AFP surveillance - Notification: Immediate report to CMO, State Health Dept, IDSP war room; IHR 2005 reporting if required National Programs & WHO Goals Program Details ------ Pulse Polio Programme PPP Launched 1995-96 in India; OPV on National Immunization Days National Polio Surveillance Project NPSP AFP surveillance across India with WHO support Global Polio Eradication Initiative GPEI Launched 1988 by WHO, Rotary International, CDC, UNICEF WHO target Global eradication of wild poliovirus WPV1 remains in Pakistan/Afghanistan India achievement Polio-free certification by WHO - 27 March 2014 ⭐ Surveillance IDSP, IHIP, AFP surveillance network --- EXAM TIPS FOR POLIO Always Mention Key Facts ------ Incubation period 7-14 days Period of communicability Stool shedding 3-6 weeks Notifiable disease Yes - AFP reporting within 24 hours Herd immunity threshold 80-85% Drug of choice None specific; supportive only Gold standard diagnosis Stool virus isolation culture Most dangerous complication Respiratory failure bulbar polio India polio-free date 27 March 2014 National program Pulse Polio Programme 1995-96 + GPEI 1988 Hallmark sign Asymmetric flaccid paralysis WITHOUT sensory loss --- This is a complete 10-mark answer structure. Just tell me the next disease you want and I'll fill the same proforma! Q: Hi A: Hi! Ready when you are. Just name the next disease and I'll fill in the full proforma for you! 😊 Q: Polio A: I already covered Polio in full detail in our previous session! Here's a quick recap of the full answer — just scroll up for the complete version, or I can re-paste any specific section you need. --- POLIOMYELITIS - Quick Summary Section Key Points ------ Agent Poliovirus RNA, Picornaviridae, 3 serotypes Type 1 most paralytic Transmission Faecal-oral; incubation 7-14 days Reservoir Human only anthroponosis Clinical Types Inapparent 90-95%, Abortive, Non-paralytic, Paralytic 2% Hallmark sign Asymmetric flaccid paralysis WITHOUT sensory loss Most dangerous Bulbar polio → respiratory failure ⭐ Diagnosis Gold std Stool virus isolation culture Treatment No specific antiviral; supportive only Vaccines OPV live, oral + IPV killed, IM India polio-free 27 March 2014 ⭐ National Program Pulse Polio Programme 1995-96; GPEI 1988 Post-polio sequela Post-Polio Syndrome PPS - 25-40 years later --- Do you want me to go deeper into any specific section, or shall we move on to the next disease? Just name it! Q: Hepatitis B A: Searching sources... A: I have comprehensive data from Goldman-Cecil Medicine, Jawetz Medical Microbiology, and Harrison's. Here is your full proforma: --- HEPATITIS B Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM --- 1. EPIDEMIOLOGY Agent Factors Epidemiological Triad Parameter Details ------ Causative agent Hepatitis B Virus HBV - DNA virus, Family Hepadnaviridae Structure Dane particle 42 nm = complete virion; 22-nm spherical/tubular particles = excess HBsAg Antigens HBsAg surface, HBcAg core, HBeAg e antigen - marker of active replication Genotypes 10 genotypes A-J; Genotype D common in India/Mediterranean; Genotype C associated with severe disease Source of infection Infected humans acute cases, chronic carriers Reservoir Human only anthroponosis Infective material Blood primary, semen, vaginal secretions, saliva, breast milk, menstrual fluid. NOT faeces Infectivity Highly infectious - up to 10¹⁰ virions/mL in blood; virus survives drying for days Pathogenicity Most acute infections self-limiting; 5-10% adults become chronic carriers; 90% neonates become chronic Host Factors Parameter Details ------ Age group All ages; neonates and young children at highest risk of chronicity Sex Males more commonly develop chronic disease and hepatocellular carcinoma Immunity Anti-HBs antibody = protective; herd immunity threshold 80-90% High-risk groups IV drug users, healthcare workers, dialysis patients, multiply transfused, organ transplant recipients, men who have sex with men, infants of HBsAg-positive mothers, sexual partners of carriers Susceptibility Immunosuppressed patients dialysis, HIV, chemotherapy respond poorly to vaccine Environmental Factors - Season/Climate: No seasonal trend - Geography: Worldwide; high endemicity in sub-Saharan Africa, East Asia, SE Asia. India is intermediate endemicity HBsAg prevalence 2-4% - Socioeconomic: Overcrowding, unsafe injection practices, lack of blood screening, poor healthcare sterilization, tattooing/piercing Transmission Parameter Details ------ Mode Parenteral blood/blood products, Sexual horizontal, Perinatal/Vertical mother to child, Close contact Routes IV drug use shared needles, unscreened blood transfusion, unsafe injections, sexual intercourse, mother-to-newborn at delivery Portal of entry Skin/mucous membranes percutaneous or mucosal exposure NOT transmitted Faecal-oral route - NOT documented Incubation period 45-180 days mean 60-90 days Period of communicability Several weeks before onset of symptoms; throughout HBsAg positivity; chronic carriers - lifelong Descriptive Epidemiology - Global burden: 350 million chronic HBV carriers worldwide; 600,000 deaths/year from HBV-related liver disease and hepatocellular carcinoma WHO; 2 billion people have been infected at some point - Indian scenario: Intermediate endemicity; prevalence of HBsAg 3.7-4%; Hepatitis B vaccine introduced into UIP in 2002; under National Viral Hepatitis Control Programme NVHCP launched 2018 - Epidemic pattern: Endemic worldwide; no seasonal epidemic pattern; notifiable disease under IDSP --- 2. CLINICAL FEATURES Stages of Disease Stage Features ------ Incubation period 45-180 days mean 60-90 days Prodromal stage Anorexia, nausea, malaise, fever, arthralgia, rash serum sickness-like reaction due to immune complexes Icteric stage Fastigium Jaundice in 1/3 adults, dark urine, pale stools, hepatomegaly, tender liver, RUQ pain Post-icteric / Convalescence Gradual resolution; jaundice clears; liver enzymes normalize Outcome 90-95% adults - full recovery; 5-10% - chronic infection Cardinal / Pathognomonic Features - Serum sickness-like prodrome arthralgia, urticaria, rash - unique to Hep B, due to HBsAg-anti-HBs immune complexes - Jaundice with marked hepatomegaly and elevated transaminases ALT AST - HBsAg positivity - pathognomonic marker in blood - Window period - HBsAg disappears but anti-HBs not yet appeared; only anti-HBc IgM positive ⭐ Clinical Types / Grades / Severity Type Features ------ Inapparent / Subclinical Majority; no symptoms, seroconversion only Acute symptomatic hepatitis B Classic icteric illness; 1/3 adults have jaundice Fulminant hepatitis B ⭐ Massive hepatic necrosis; hepatic encephalopathy; 1% but 60-80% mortality Chronic hepatitis B HBsAg persists 6 months; 5-10% adults, 90% neonates Carrier state HBsAg positive, no active liver disease --- 3. DIAGNOSIS Lab Investigations Investigation Details ------ Routine labs LFT: raised ALT/AST ALT AST, raised bilirubin; CBC; PT/INR for severity; USG abdomen HBsAg First marker to appear; positive from 2-6 weeks before symptoms; persistence 6 months = chronic infection Anti-HBc IgM Marker of acute infection; present during "window period" ⭐ HBeAg Marker of active viral replication and high infectivity HBV DNA PCR Quantitative viral load; gold standard for assessing replication and treatment monitoring Anti-HBs Marker of recovery and immunity also post-vaccination Serological Interpretation Table ⭐ Phase HBsAg Anti-HBc IgM Total Anti-HBc Anti-HBs --------------- Incubation + +/- +/- - Acute hepatitis + + + - Window period - + + - Recovery - - + + Vaccination - - - + Chronic carrier + - + - Case Definition WHO / IDSP Definition Criteria ------ Suspected case Clinical jaundice + epidemiological risk factors Probable case Clinical hepatitis + raised transaminases Confirmed case HBsAg positive OR anti-HBc IgM positive in acute setting Chronic case HBsAg positive for 6 months Notifiable? YES - notifiable under IDSP; report to CMO --- 4. TREATMENT General / Supportive Care - Bed rest during acute phase - High-calorie, low-fat diet; adequate hydration - Avoid hepatotoxic drugs paracetamol in excess, alcohol, rifampicin - Monitor liver function tests, PT/INR, mental status - Glucocorticoids are CONTRAINDICATED ⭐ Specific Treatment Parameter Details ------ Acute Hep B Usually no antiviral needed; spontaneous recovery in 95% Severe acute Hep B Antiviral indicated if coagulopathy, persistent symptoms 4 weeks, marked jaundice Drug of choice chronic Tenofovir Disoproxil Fumarate TDF 245 mg/day OR Tenofovir Alafenamide TAF 25 mg/day OR Entecavir 0.5 mg/day Alternatives Pegylated Interferon alfa-2a finite duration, immune-mediated Second-line Lamivudine resistance common - avoid as first-line, Adefovir, Telbivudine Special populations Pregnancy: TDF preferred; Paediatrics: Entecavir or TDF; HIV co-infection: TDF + Emtricitabine both cover HBV and HIV Fulminant hepatitis Intensive care; consider liver transplantation Post-exposure Prophylaxis PEP - HBIG Hepatitis B Immune Globulin + HBV vaccine given simultaneously at different sites within 24 hours of exposure ⭐ - For neonate born to HBsAg-positive mother: HBIG + Hep B vaccine within 12 hours of birth Isolation & Notification - Isolation type: Blood and body fluid precautions not enteric isolation - Duration: Until HBsAg negative - Notification: Compulsory - notify CMO under IDSP; notifiable under IHR 2005 --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ Immediate / Acute ⭐ Fulminant hepatic failure most dangerous - 1% but high mortality Hepatic chronic Chronic active hepatitis → Liver cirrhosis → Hepatocellular carcinoma HCC ⭐ Extrahepatic Polyarteritis nodosa PAN, membranous glomerulonephritis, cryoglobulinaemia, aplastic anaemia Neurological Guillain-Barre syndrome rare Coinfection HDV Hepatitis D - only infects HBsAg-positive patients; causes more severe disease ⭐ Long-term sequelae HCC - HBV is the 1 cause of HCC worldwide; 25% of chronic carriers develop cirrhosis/HCC Complications of treatment Renal toxicity with TDF; lactic acidosis with nucleoside analogues; HBV flare on stopping antivirals ⭐ Most dangerous acute complication: Fulminant hepatic failure ⭐ Most important long-term complication: Hepatocellular carcinoma HCC --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Health education about routes of transmission and risk behaviors - Safe sex practices condom use - Avoid sharing needles, razors, toothbrushes - Safe tattooing and ear-piercing practices - Screening of blood donors HBsAg, HBcAb, HBV DNA - Sterilization of medical/surgical equipment Primary Prevention - Specific Protection Immunization Active: Feature Details ------ Vaccine type Recombinant DNA subunit vaccine HBsAg produced in yeast Schedule India UIP Birth dose within 24 hrs + 6, 10, 14 weeks as Pentavalent vaccine Route Intramuscular deltoid in adults; anterolateral thigh in infants Efficacy 90-95% in immunocompetent individuals Seroprotection Anti-HBs ≥10 mIU/mL = protected Introduced in India UIP 2002 initially 10 states; universal by 2011 Booster Not recommended for immunocompetent persons after primary series Passive Immunization: - HBIG 0.06 mL/kg IM - for post-exposure prophylaxis; given with vaccine simultaneously Chemoprophylaxis: TDF can be given to pregnant HBsAg-positive women with high viral load HBV DNA 200,000 IU/mL in third trimester to prevent vertical transmission Universal Precautions: For all healthcare workers - gloves, masks, sharp disposal Secondary Prevention - Screening of pregnant women for HBsAg - all antenatal women screened under NVHCP - Screening of blood donors - mandatory HBsAg, HBcAb, HBV DNA testing - Active case finding in high-risk groups dialysis units, HIV patients - Contact tracing of HBsAg-positive index cases; vaccination of susceptible contacts - Surveillance under IDSP and NVHCP Tertiary Prevention - Rehabilitation - Long-term antiviral therapy to prevent cirrhosis and HCC - Regular monitoring: 6-monthly LFT, HBV DNA, AFP + USG abdomen for HCC screening - Management of cirrhosis complications ascites, varices, hepatic encephalopathy - Liver transplantation for end-stage liver disease - Psychosocial support and vocational rehabilitation Control Measures During an Outbreak - Case identification and notification to CMO and IDSP - Contact tracing - test all household and sexual contacts for HBsAg/anti-HBs; vaccinate susceptible contacts - Safe injection practices enforced in outbreak setting - Concurrent disinfection of blood-contaminated surfaces with 1% sodium hypochlorite - Epidemiological investigation - identify common source blood bank, healthcare facility National Programs & WHO Goals Program Details ------ National Viral Hepatitis Control Programme NVHCP Launched 28 July 2018 World Hepatitis Day by Ministry of Health, India ⭐ Universal Immunization Programme UIP Hep B vaccine as part of Pentavalent vaccine since 2002 WHO target Eliminate viral hepatitis as public health threat by 2030 SDG 3.3; 90% reduction in new infections, 65% reduction in mortality World Hepatitis Day 28 July every year ⭐ Surveillance IDSP, IHIP, NVHCP portal --- EXAM TIPS FOR HEPATITIS B Always Mention Key Facts ------ Incubation period 45-180 days mean 60-90 days Period of communicability Throughout HBsAg positivity Notifiable Yes - under IDSP Herd immunity threshold 80-90% Drug of choice chronic Tenofovir TDF/TAF or Entecavir Gold standard diagnosis HBsAg + HBV DNA PCR Window period marker Anti-HBc IgM ⭐ Most dangerous complication Fulminant hepatic failure acute; HCC long-term Not transmitted by Faecal-oral route National program NVHCP 2018 World Hepatitis Day 28 July Post-exposure prophylaxis HBIG + Vaccine within 24 hours Unique prodrome Serum sickness-like arthralgia + rash --- Ready for the next disease! Just name it. Q: Diarrhoeah A: Searching sources... A: Excellent - I have comprehensive data. Here is your full proforma: --- DIARRHOEAL DISEASES Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM Note for exam: Diarrhoeal disease is a syndrome, not a single disease. In PSM exams, questions may ask about diarrhoea as a group or specifically about Cholera, Rotavirus, or Dysentery. This proforma covers the group - always specify causative agents where asked. --- 1. EPIDEMIOLOGY Agent Factors Epidemiological Triad Parameter Details ------ Causative agents Multiple - see below Viruses 70-80% in children Rotavirus 1 cause globally in 5 years, Norovirus, Astrovirus, Adenovirus Bacteria 10-20% Vibrio cholerae, E. coli ETEC, EPEC, EIEC, EHEC, Shigella spp., Salmonella spp., Campylobacter jejuni, Clostridium difficile, Staph. aureus Protozoa 10% Entamoeba histolytica, Giardia lamblia, Cryptosporidium Source of infection Infected humans, animals zoonotic - Salmonella, Campylobacter, environment V. cholerae in water Reservoir Human Shigella, Cholera, Animal Salmonella, Campylobacter, Environment Cholera - aquatic Infective material Faeces, vomitus Norovirus, contaminated food and water Infective dose Varies - Shigella/EHEC: as few as 10-100 organisms; V. cholerae: 10⁵-10⁸ organisms needed Pathogenicity High - especially in malnourished children; malnutrition and diarrhoea form a vicious cycle Host Factors Parameter Details ------ Age group All ages; highest morbidity and mortality in children 5 years Sex No significant difference Immunity Varies by pathogen; limited cross-protection between types Risk factors Malnutrition, bottle feeding vs breastfeeding, lack of handwashing, immunocompromise HIV, extremes of age Protective factors Breastfeeding secretory IgA, Rotavirus vaccination, good nutritional status, vitamin A Environmental Factors - Season/Climate: Bacterial diarrhoea peaks in summer heat favors bacterial growth; viral diarrhoea Rotavirus peaks in winter/cool dry season in tropical countries - Geography: High burden in South Asia, Sub-Saharan Africa; India - high endemicity especially in 5 years age group - Socioeconomic: Unsafe water supply, open defecation, poor sanitation, overcrowding, poverty, lack of hand-washing facilities, improper food storage/handling Transmission Parameter Details ------ Mode Faecal-oral primary route for ALL diarrhoeal pathogens Routes - 5 Fs Fluids water, Food, Fingers hands, Flies, Fomites Vehicle Contaminated water cholera, typhoid, food Salmonella, Staph., person-to-person contact Shigella, Rotavirus Portal of entry GI tract oral ingestion Incubation period Varies: Staph. aureus toxin: 1-6 hrs; Salmonella: 6-48 hrs; Shigella: 1-3 days; Rotavirus: 1-3 days; Cholera: few hours - 5 days; Giardia: 1-3 weeks Period of communicability Throughout symptomatic phase; asymptomatic carriers can shed for weeks Salmonella typhi - up to 1 year Descriptive Epidemiology - Global burden: Diarrhoea is the 8th leading cause of death overall; 3rd leading cause of death in children 5 years; responsible for 1.6 million deaths worldwide/year; 500,000 deaths/year in children 5 years Rosen's EM, 2021 - Indian scenario: India has one of the highest burdens of diarrhoeal disease; under Integrated Management of Neonatal and Childhood Illness IMNCI and National Oral Rehydration Therapy ORT Programme; Rotavirus vaccine introduced into UIP in 2016 - Epidemic pattern: Endemic worldwide with epidemic potential cholera; sporadic food poisoning; seasonal peaks; cholera - pandemic 7 pandemics, currently 7th pandemic ongoing, caused by El Tor biotype --- 2. CLINICAL FEATURES Stages of Disease Stage Features ------ Incubation Hours to weeks depending on pathogen Prodromal Nausea, anorexia, abdominal discomfort, borborygmi Acute phase Fastigium Loose/watery/bloody stools, abdominal cramps, fever in invasive, vomiting, tenesmus in dysentery Convalescence Stool frequency and consistency normalize; fluid and electrolyte balance restored Classification of Diarrhoea By Duration: - Acute: 14 days - Persistent: 14-30 days - Chronic: 30 days By Pathophysiology: Type Mechanism Example --------- Secretory Enterotoxin → ↑cAMP/cGMP → ↑Cl⁻ secretion, ↓Na⁺ absorption Cholera V. cholerae, ETEC Osmotic Poorly absorbed solutes retain water in gut lumen Viral gastroenteritis Rotavirus, Giardia Inflammatory / Dysenteric Mucosal invasion → cytotoxin → inflammation Shigella, EIEC, Entamoeba histolytica Motility-related Altered gut motility IBS non-infectious By Clinical Type: Type Features Common Agents --------- Watery diarrhoea Large-volume, watery stools, NO blood; rapid dehydration Cholera, Rotavirus, ETEC Dysentery bloody diarrhoea Small-volume, bloody mucoid stools, tenesmus, fever Shigella, EIEC, Entamoeba histolytica, EHEC Food poisoning Short incubation, vomiting prominent, no fever Staph. aureus, C. perfringens Cardinal / Pathognomonic Features - Dehydration signs: Sunken eyes, dry mouth, reduced skin turgor, depressed fontanelle infants, reduced urine output ⭐ - Rice-water stools - pathognomonic of Cholera profuse, watery, fishy/musty odour - Bloody mucoid stools + tenesmus - characteristic of Shigella Bacillary dysentery - "Starvation stools" - watery green stools in malnourished children - Raspberry jelly stools - Entamoeba histolytica amoebic dysentery WHO Dehydration Assessment ⭐ Sign No Dehydration Some Dehydration Severe Dehydration ------------ General condition Well, alert Restless, irritable Lethargic/unconscious Eyes Normal Sunken Very sunken Thirst Normal Thirsty, drinks eagerly Drinks poorly/cannot drink Skin pinch Goes back quickly Goes back slowly Goes back very slowly 2 sec Action Home ORS Plan A ORS in facility Plan B IV fluids Plan C --- 3. DIAGNOSIS Lab Investigations Investigation Details ------ Clinical diagnosis History of loose stools + dehydration; assess duration, frequency, blood/mucus, fever Routine labs Stool examination macroscopic + microscopic - RBCs, pus cells, parasites, cysts; CBC; serum electrolytes; BUN/creatinine for severity Stool culture Gold standard for bacterial diarrhoea; identify pathogen and antibiotic sensitivity Stool microscopy Motile trophozoites of E. histolytica = amoebic dysentery; cysts = Giardia; RBCs in dysentery Rapid tests Cholera RDT rapid dipstick; Rotavirus ELISA/antigen test PCR For viral identification Norovirus, Rotavirus Hanging drop preparation Darting motility of V. cholerae - confirms cholera Case Definition WHO / IDSP Definition Criteria ------ Acute Diarrhoea ≥3 loose/watery stools in 24 hours Dysentery Blood and/or mucus in stools Cholera Suspected Acute watery diarrhoea with/without vomiting, in patient ≥5 years, with severe dehydration Cholera Confirmed V. cholerae O1 or O139 isolated from stool culture Notifiable? YES - Cholera is notifiable under IDSP and under IHR 2005 potential PHEIC; all clusters/outbreaks must be reported to CMO within 24 hours --- 4. TREATMENT General / Supportive Care - ORS is the Cornerstone ⭐ The basis of ORS works because: The sodium-glucose co-transport mechanism in the gut remains intact during secretory diarrhoea - glucose actively carries sodium and water across the enterocyte even when cholera toxin is acting. WHO-ORS Composition Low-osmolarity ORS - 2003: Component Amount per litre ------ Sodium chloride 2.6 g Trisodium citrate 2.9 g Potassium chloride 1.5 g Glucose anhydrous 13.5 g Total osmolarity 245 mOsm/L Home ORS Sugar-Salt Solution: 1 teaspoon salt + 8 teaspoons sugar in 1 litre clean water ORS Plans: Plan Dehydration Setting Amount ------------ Plan A None Home 50-100 mL ORS after each loose stool Plan B Some Facility 75 mL/kg over 4 hours Plan C Severe Hospital IV Ringer's Lactate 100 mL/kg infants: over 3 hrs; children: over 1 hr Zinc supplementation: 20 mg/day for 14 days in children 10 mg/day in 6 months ⭐ - reduces duration and severity; recommended by WHO since 2004 Continue feeding: Early re-feeding; do NOT withhold food; breastfeeding should continue Specific Treatment Pathogen Drug of Choice Dose/Duration --------- Cholera Doxycycline adults / Azithromycin children/pregnant Doxycycline 300 mg single dose; Azithromycin 1g single dose Shigella Bacillary dysentery Ciprofloxacin adults / Azithromycin children Cipro 500 mg BD x 3 days Amoebic dysentery Metronidazole + Diloxanide furoate Metro 800 mg TDS x 5-10 days luminal agent follows Giardia Metronidazole or Tinidazole Metro 400 mg TDS x 5 days ETEC Traveller's diarrhoea Usually self-limiting; Rifaximin if needed Rifaximin 200 mg TDS x 3 days C. difficile Vancomycin oral or Fidaxomicin Vancomycin 125 mg QDS x 10 days Rotavirus/viral Supportive only ORS + Zinc No antivirals Antibiotics NOT routinely recommended for acute watery diarrhoea - reserve for cholera, dysentery, and specific confirmed bacterial causes Isolation & Notification - Isolation type: Enteric precautions contact precautions for C. difficile - Duration: Until symptoms resolve and 2 stool cultures negative for cholera - Notification: Cholera - compulsory notification to CMO; report to State/IHR 2005; all outbreaks reported to IDSP --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ Immediate / Acute ⭐ Severe dehydration → Hypovolaemic shock → Death most dangerous, especially 5 years Metabolic Hyponatraemia, Hypokalaemia, Metabolic acidosis Renal Acute kidney injury pre-renal from dehydration Neurological Febrile seizures Rotavirus, Shigella; Encephalopathy Shigella - Ekiri syndrome; Haemolytic Uraemic Syndrome HUS from EHEC E. coli O157:H7 ⭐ GI Intussusception post-Rotavirus; Toxic megacolon Shigella, C. difficile; Intestinal perforation; Rectal prolapse Shigella in malnourished Nutritional Malnutrition and growth faltering persistent/chronic diarrhoea Long-term Post-infectious IBS; Reactive arthritis Reiter's syndrome - after Shigella, Salmonella, Campylobacter Treatment complications Hypernatraemia from incorrect ORS preparation; antibiotic resistance ⭐ Most dangerous complication: Severe dehydration → Hypovolaemic shock ⭐ Important specific complication: HUS from EHEC E. coli O157:H7 - microangiopathic haemolytic anaemia + thrombocytopenia + acute kidney injury --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Health education: handwashing with soap especially before meals, after defecation ⭐ - Safe water supply - boiling, chlorination, filtration - Proper food hygiene: cook food thoroughly, refrigerate properly, avoid raw/street food - Sanitation: use of latrines, ODF Open Defecation Free campaigns - Swachh Bharat Mission ⭐ - Breastfeeding promotion protective IgA, no contaminated water - Nutritional improvement - Vitamin A supplementation reduces severity Primary Prevention - Specific Protection Immunization: Vaccine Disease Type Schedule India UIP ------------ Rotavirus vaccine RVV Rotavirus diarrhoea Live attenuated oral 6, 10, 14 weeks introduced in India UIP 2016 ⭐ Oral Cholera Vaccine OCV Cholera Killed oral Shanchol/OrcVax 2 doses, 2 weeks apart; used in outbreak settings Typhoid vaccine Typhoid enteric fever Vi polysaccharide / TCV UIP: Typhoid Conjugate Vaccine TCV from 9-12 months Chemoprophylaxis: Not recommended routinely; Doxycycline for household contacts of confirmed cholera cases in some guidelines Water purification: Chlorination 0.5 ppm residual chlorine, boiling, UV purification Personal protection: Hand hygiene 5 moments of hand hygiene, safe food handling Secondary Prevention - ORT Programme - early treatment with ORS at community level; ORS corners in PHCs/subcentres - Zinc supplementation added to ORS since 2004 WHO/UNICEF recommendation - IMNCI Integrated Management of Neonatal and Childhood Illness - community-level case management by ASHA/ANM - IDSP surveillance - alert system for cluster of diarrhoea cases - Rapid reporting and investigation of outbreaks - Stool culture surveillance to identify dominant pathogens Tertiary Prevention - Rehabilitation - Nutritional rehabilitation after episode F-75 → F-100 formula in SAM - Growth monitoring and promotion - Long-term follow-up for persistent/chronic cases - Management of post-diarrhoeal malnutrition and stunting Control Measures During an Outbreak - Case isolation: Enteric precautions for all cases - Contact tracing: Identify source water supply, food handler, common meal - Water safety: Immediate chlorination of water supply; test water samples - Disinfection: Concurrent bleach on faeces/vomit + terminal disinfection - Food handler screening: Stool culture of all food handlers - Epidemiological investigation: Attack rate, epidemic curve, spot map; identify point source vs propagated source - Notification: Report to CMO, IDSP war room; cholera under IHR 2005 National Programs & WHO Goals Program Details ------ National ORT Programme Promotion of ORS at all levels; ORS packets distributed through ASHA/AWW National Zinc Programme Zinc co-administered with ORS since WHO 2004 recommendation Swachh Bharat Mission SBM Launched 2 Oct 2014; ODF India declared 2019; critical for diarrhoea prevention ⭐ IMNCI Community management of childhood diarrhoea by front-line health workers Rotavirus vaccine in UIP Introduced April 2016; phased rollout across India ⭐ Jal Jeevan Mission Piped tap water to all rural households by 2024 - major diarrhoea prevention tool WHO target End preventable child deaths; reduce under-5 mortality SDG 3.2 Surveillance IDSP, IHIP, NVBDCP for cholera, HMIS --- EXAM TIPS FOR DIARRHOEAL DISEASES Always Mention Key Facts ------ Incubation period Varies by agent Staph 1-6 hrs → Giardia 1-3 weeks Period of communicability Throughout symptomatic period Notifiable Cholera - YES IHR 2005 PHEIC; all outbreaks under IDSP Most common cause in children Rotavirus globally; Norovirus post-vaccination era in US Drug of choice for Cholera Doxycycline single dose adults Drug of choice for Amoebic dysentery Metronidazole + Diloxanide furoate Cornerstone of treatment ORS Plan A/B/C + Zinc ⭐ Most dangerous complication Severe dehydration → shock HUS caused by EHEC E. coli O157:H7 ⭐ National program Swachh Bharat Mission 2014 + ORT Programme + Rotavirus vaccine UIP 2016 Rice-water stools Cholera pathognomonic Raspberry jelly stools Amoebic dysentery ORS osmolarity 245 mOsm/L low osmolarity WHO formula, 2003 Zinc dose 20 mg/day x 14 days 10 mg in 6 months --- Great coverage for a PSM exam! Just name the next disease. Q: Cholera A: Searching sources... A: I have comprehensive data from Harrison's and Goldman-Cecil. Here is your full proforma: --- CHOLERA Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM --- 1. EPIDEMIOLOGY Agent Factors Epidemiological Triad Parameter Details ------ Causative agent Vibrio cholerae - curved Gram-negative bacillus, Family Vibriaceae Serogroups O1 and O139 epidemic potential; non-O1/non-O139 cause sporadic disease only Biotypes of O1 Classic caused pandemics 1-6; now extinct and El Tor 7th pandemic; currently ongoing ⭐ Serotypes of O1 Inaba, Ogawa, Hikojima O139 Emerged 1992 in southeastern India; Bengal serogroup; not cross-protective with O1 Virulence factor Cholera Toxin CT - A+B subunits; B binds GM1 ganglioside → A subunit ADP-ribosylates Gs protein → ↑cAMP → ↑Cl⁻ secretion + ↓Na⁺ absorption → massive fluid loss ⭐ Source of infection Infected humans cases + carriers; aquatic environment Reservoir Aquatic estuaries, brackish water, plankton/copepods; Human gut Infective material Faeces primarily, vomitus Infective dose 10³-10⁸ via water; 10²-10⁴ via food gastric acid provides partial protection Pathogenicity El Tor: more asymptomatic cases than classic biotype; O blood group at highest risk of severe disease Host Factors Parameter Details ------ Age group Children 2 years in endemic areas; all ages in epidemics/new areas Sex No significant difference Blood group Blood group O → highest risk of severe disease ⭐; Blood group AB → least risk Immunity Natural infection confers immunity for 3 years; type-specific O1 immunity does NOT protect against O139 Susceptibility increased by Achlorhydria, H. pylori infection hypochlorhydria, use of PPIs/antacids, malnutrition Herd immunity threshold 60-80% vaccine-dependent Environmental Factors - Season/Climate: Hot season peaks; associated with high temperatures, flooding, monsoon; El Niño events increase cholera via promoting plankton blooms - Geography: Endemic in Africa, South Asia Ganges delta - native origin, Latin America; 7th pandemic ongoing; India - endemic in parts of Bengal, Bihar, Odisha; notifiable - Socioeconomic: Unsafe water, poor sanitation, open defecation, poverty, war/displacement, flooding, breakdown of health infrastructure Transmission Parameter Details ------ Mode Faecal-oral primarily waterborne; also foodborne Vehicle Contaminated water 1, contaminated food shellfish, raw seafood, rice, vegetables, hands Portal of entry GI tract oral ingestion No animal reservoir Anthroponosis humans only for transmission; environment is a reservoir Person-to-person Less common large inoculum needed; but household attack rate 50% in endemic areas Incubation period Few hours to 5 days usually 24-48 hours ⭐ Period of communicability Throughout symptomatic phase stool positive; El Tor carriers shed for weeks to months; chronic gallbladder carrier state possible Descriptive Epidemiology - Global burden: True burden estimated at 1-4 million cases/year; 20,000-140,000 deaths/year severe underreporting - only 400,000 reported to WHO/year; major outbreaks in Haiti 2010-2022, Yemen 2016-2017, Africa currently ⭐ - 7 Pandemics: First in 1817 Ganges delta, India; 7th pandemic began 1961 in Indonesia El Tor biotype; currently ongoing; O139 emerged India 1992 - Indian scenario: Cholera endemic in several states; notifiable disease under IDSP; National Cholera Control Programme; outbreaks during floods/post-disaster - Epidemic pattern: Endemic with epidemic/pandemic potential; point-source outbreaks contaminated water supply + propagated spread; classic epidemic curve = explosive point-source --- 2. CLINICAL FEATURES Stages of Disease Stage Features ------ Incubation period Few hours to 5 days usually 24-48 hours Prodromal stage Usually absent - sudden onset Acute phase Fastigium Sudden painless profuse watery diarrhoea ± vomiting; NO fever; muscle cramps Progression Rapid dehydration → shock → death if untreated can die within hours Convalescence Full recovery with adequate rehydration; self-limiting in 2-5 days Cardinal / Pathognomonic Features ⭐ - "Rice-water stools" - profuse, watery, non-bilious, gray, cloudy with mucus flecks, slightly fishy odour - PATHOGNOMONIC ⭐ - Painless diarrhoea no tenesmus, no blood - due to secretory mechanism, not invasion - NO fever distinguishes from dysentery - "Washerwoman's hands/skin" - severe wrinkling of skin from dehydration ⭐ - Sunken eyes, sunken fontanelle infants, loss of skin turgor - Hypotension, rapid weak pulse hypovolaemic shock - "Cholera voice" vox choleraica - hoarse whisper from dehydration - Muscle cramps hypokalaemia, hyponatraemia - Stool output can exceed 250 mL/kg/24 hours in severe cases Dehydration Grading Degree Clinical Signs % Body Weight Loss --------- None/Mild Thirst only 5% Moderate Thirst, postural hypotension, tachycardia, decreased skin turgor, dry mucosa 5-10% Severe ⭐ Unconscious/lethargic, absent pulse, sunken eyes, cannot drink, washerwoman skin 10% Clinical Types Type Features ------ Asymptomatic Majority El Tor biotype especially; subclinical infection Cholera sicca Severe form with massive fluid sequestration in gut but minimal external diarrhoea; severe shock; often fatal before diarrhoea appears ⭐ Cholera gravis Classic severe cholera with profuse rice-water diarrhoea, rapid dehydration, shock Mild cholera Watery diarrhoea resembling ordinary gastroenteritis; self-limiting --- 3. DIAGNOSIS Lab Investigations Investigation Details ------ Clinical diagnosis Patient ≥5 years + acute watery diarrhoea + severe dehydration in endemic/epidemic area Routine labs Elevated haematocrit haemoconcentration, elevated BUN/creatinine, ↓bicarbonate 15 mmol/L, elevated anion gap, low arterial pH 7.2, normal Na⁺/K⁺/Cl⁻ initially Stool microscopy Hanging drop ⭐ Darting motility "shooting star" motility of vibrios; immobilisation by specific O1 antisera confirms diagnosis Dark field microscopy Curved rods with characteristic motility in fresh stool Stool culture Gold standard ⭐ Selective media: TCBS agar Thiosulphate Citrate Bile Salt Sucrose - yellow colonies; or Alkaline Peptone Water APW enrichment broth pH 8.6 Rapid diagnostic test RDT Cholera RDT dipstick - bedside; useful in field/outbreak settings PCR For O1/O139 confirmation and biotyping Serology Vibriocidal antibody titres - for epidemiological studies Case Definition WHO / IDSP Definition Criteria ------ Suspected case Patient ≥5 years with acute watery diarrhoea and severe dehydration OR death from acute watery diarrhoea, in a cholera-affected area Confirmed case Suspected case + V. cholerae O1 or O139 isolated from stool Notifiable? ⭐ YES - Cholera is a MANDATORY notifiable disease under IDSP; also under IHR 2005 - potential Public Health Emergency of International Concern PHEIC; report to CMO within 24 hours --- 4. TREATMENT General / Supportive Care - Rehydration is EVERYTHING ⭐ "The death from cholera is due to hypovolaemic shock; thus treatment first and foremost requires fluid resuscitation." - Harrison's ORS - Why it works: Glucose-Na⁺ co-transport in the gut remains intact even when cholera toxin is active → oral rehydration possible Rehydration Plans: Severity Treatment Volume --------- None/Mild Plan A ORS at home 50-100 mL after each loose stool Moderate Plan B ORS in facility Age/weight-based e.g., ≥15 years: 2200-4000 mL over 4 hrs Severe Plan C ⭐ IV Ringer's Lactate 100 mL/kg in first 3 hours adults; 6 hours children 12 months; start RAPIDLY then slow If Ringer's Lactate unavailable → Normal Saline 0.9% NaCl Reassess every 15-30 minutes during IV resuscitation Continue feeding after rehydration; breastfeeding must continue Specific Treatment Parameter Details ------ Antibiotics Shorten duration of diarrhoea and reduce fluid loss by 50%; NOT a substitute for rehydration Drug of choice adults ⭐ Doxycycline 300 mg - single dose most effective, cheapest Drug of choice children Azithromycin 20 mg/kg - single dose Drug of choice pregnant Azithromycin 1g - single dose Alternatives Tetracycline 500 mg QDS x 3 days; Ciprofloxacin 1g single dose; Erythromycin Resistance Tetracycline/doxycycline resistance reported from Bangladesh, India; check local antibiogram Zinc supplementation 20 mg/day x 14 days in children adjunct Isolation & Notification - Isolation type: Enteric/contact precautions; strict stool/vomit disposal - Duration: Until 3 consecutive stool cultures are negative - Notification: Immediate within 24 hours to CMO; report to State Health Dept; IDSP war room; IHR 2005 reporting if international spread suspected --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ Immediate / Acute ⭐ Hypovolaemic shock → Death most dangerous; can occur within 4-12 hours of onset Metabolic Hypokalaemia muscle cramps, cardiac arrhythmia, Metabolic acidosis, Hyponatraemia Renal Acute Kidney Injury / Acute Tubular Necrosis from profound hypoperfusion ⭐ Cardiovascular Cardiac arrhythmias from hypokalaemia; circulatory collapse Pulmonary Aspiration pneumonia from vomiting in obtunded patient Obstetric Intrauterine fetal death, premature labour in pregnant women Treatment complications Fluid overload cerebral oedema in children if over-rapid rehydration; antibiotic resistance "Cholera sicca" Paradoxical - death from shock before diarrhoea appears fluid sequestered in gut ⭐ ⭐ Most dangerous complication: Hypovolaemic shock - can kill in hours With adequate rehydration: case fatality rate CFR 1%; without treatment: CFR 25-50% --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Safe water supply: chlorination 0.5 ppm residual chlorine, boiling, filtration - Proper sanitation: use of latrines; ODF campaigns Swachh Bharat Mission - Hand-washing with soap: especially before food and after defecation - Food hygiene: avoid raw/undercooked shellfish and seafood; cook food thoroughly - Proper disposal of faeces and vomitus - Avoid use of raw sewage as fertiliser Primary Prevention - Specific Protection Immunization: Vaccine Type Efficacy Schedule ------------ Shanchol OCV Killed oral bivalent O1 + O139 65-85% for 2 years 2 doses, 2 weeks apart ≥1 year of age ⭐ OrcVax mORCVAX Killed oral Similar 2 doses Dukoral Killed oral + recombinant B subunit 85% short-term 2 doses travellers Old killed parenteral vaccine Killed parenteral injectable Only 50%; short duration No longer recommended ⭐ Cholera vaccine is NOT included in India's UIP - used in outbreak/endemic settings and for travellers Chemoprophylaxis: Doxycycline for household contacts in some protocols not routinely recommended - may mask cases and create resistance Personal protection: Boil water; avoid raw foods; hand hygiene Secondary Prevention - Active case finding - identify all cases in community rapidly - Surveillance under IDSP - any cluster of acute watery diarrhoea is an alert - Water quality monitoring - regular testing of water supply for coliforms - Contact tracing - screen and observe household contacts - Stool culture of contacts - identify asymptomatic carriers Tertiary Prevention - Rehabilitation - Nutritional rehabilitation post-recovery - Fluid/electrolyte correction for residual deficits - Renal function monitoring post-AKI - Psychological support for affected communities Control Measures During an Outbreak ⭐ - Case isolation: Enteric precautions; dedicated cholera cots holes cut for stool collection and measurement - Contact tracing: All household contacts observed; prophylaxis if appropriate - Water safety: Emergency chlorination; ban on contaminated water source; boil-water advisory - Food safety: Identify and close contaminated food sources; screen food handlers - Disinfection: Concurrent ongoing with 1% bleach/sodium hypochlorite; terminal disinfection - Cholera Treatment Centre CTC: Dedicated facility; Oral Rehydration Corners ORC - Epidemiological investigation: Identify source point vs propagated, attack rate, epidemic curve - Mass vaccination OCV: WHO recommends reactive vaccination in outbreaks alongside WASH measures - Notification: CMO → State → Centre → IHR 2005 WHO - Media management: Prevent panic while warning community National Programs & WHO Goals Program Details ------ National Cholera Control Programme India - surveillance, case management, OCV stockpile Swachh Bharat Mission Launched 2 Oct 2014; ODF India - major preventive tool ⭐ Jal Jeevan Mission Safe piped water to all rural households - key prevention IDSP All outbreaks and cases reported; War room surveillance WHO Global Task Force on Cholera Control GTFCC "Ending Cholera: A Global Roadmap to 2030" - target 90% reduction in cholera deaths by 2030 ⭐ Global OCV Stockpile WHO/UNICEF/MSF maintain emergency oral cholera vaccine stockpile for outbreak response IHR 2005 Cholera - potential PHEIC; international notification mandatory --- EXAM TIPS FOR CHOLERA Always Mention Key Facts ------ Incubation period Few hours to 5 days usually 24-48 hrs Period of communicability Throughout symptomatic phase; El Tor - weeks in carriers Notifiable YES - IHR 2005 + IDSP mandatory Causative agent V. cholerae O1 El Tor biotype / O139 7th Pandemic began 1961, Indonesia El Tor biotype ⭐ Pathognomonic sign Rice-water stools + washerwoman skin ⭐ Drug of choice Doxycycline 300 mg single dose adults ⭐ Cornerstone of treatment Rehydration ORS Plan A/B; Ringer's Lactate Plan C ⭐ Gold standard diagnosis Stool culture on TCBS agar ⭐ Hanging drop test Darting motility of vibrios Most dangerous complication Hypovolaemic shock CFR 25-50% untreated; 1% treated Blood group risk Blood group O = highest risk ⭐ Cholera toxin mechanism ↑cAMP → ↑Cl⁻ secretion → rice-water stool ⭐ WHO 2030 goal 90% reduction in cholera deaths --- Ready for the next disease! Just name it. Q: Cjolera A: I think you meant Cholera again! I already covered it in full detail just above. Here's a quick recap: --- CHOLERA - Quick Summary Section Key Points ------ Agent Vibrio cholerae O1 El Tor biotype / O139; curved Gram-negative bacillus Reservoir Aquatic environment + human gut; NO animal reservoir Transmission Faecal-oral; contaminated water 1; incubation 24-48 hrs Pathognomonic ⭐ Rice-water stools + washerwoman skin; NO fever, NO blood Virulence Cholera toxin → ↑cAMP → massive Cl⁻/water secretion Diagnosis Gold std Stool culture on TCBS agar; hanging drop = darting motility Treatment ⭐ Rehydration FIRST ORS/Ringer's Lactate + Doxycycline 300 mg single dose Most dangerous Hypovolaemic shock CFR 25-50% untreated; 1% with treatment Vaccine Shanchol killed oral, 2 doses - NOT in UIP 7th Pandemic 1961, Indonesia El Tor biotype; currently ongoing WHO 2030 goal 90% reduction in cholera deaths --- Scroll up for the complete full proforma. Ready for the next disease - just name it! 😊 Q: Typhoid A: Searching sources... A: Excellent - I have rich data from Harrison's, Park's PSM textbook, and Tintinalli's. Here is your complete proforma: --- TYPHOID FEVER ENTERIC FEVER Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM --- 1. EPIDEMIOLOGY Agent Factors Epidemiological Triad Parameter Details ------ Causative agent Salmonella typhi primary; S. paratyphi A, B, C paratyphoid - milder disease Type Gram-negative bacillus, Family Enterobacteriaceae; facultative intracellular pathogen Antigens O antigen somatic - rises in disease, H antigen flagellar - rises with vaccination, Vi antigen virulence capsular antigen - present in 80% of chronic carriers ⭐ Phage types At least 80 phage types - used for epidemiological tracing of outbreaks Source of infection Faeces and urine of cases/carriers primary; contaminated water, food, fingers, flies secondary Reservoir Human only - strict anthroponosis NO animal reservoir ⭐ Infective material Faeces primary, urine Survival Survives in water 7 days; ice and ice cream 1 month; soil irrigated with sewage up to 70 days; multiplies rapidly in milk Carrier state Temporary incubatory, convalescent and Chronic excrete 1 year, usually in gall bladder; 2-5% of cases become chronic carriers; "Typhoid Mary" - famous example ⭐ MDR strains Resistance to chloramphenicol + ampicillin + cotrimoxazole = MDR S. typhi; XDR extensively drug resistant strains also reported from Pakistan Host Factors Parameter Details ------ Age group Any age; highest incidence in 5-19 years; school-age and young adults ⭐ Sex More cases in males greater exposure; but carrier rate higher in females ⭐ Immunity Cell-mediated immunity CMI is primary defence intracellular organism; antibodies are secondary; natural infection does NOT always confer solid immunity Susceptibility increased by Achlorhydria, H. pylori infection, PPIs, malnutrition, immunocompromise Chronic carrier risk Higher in women, infants, those with biliary abnormalities or Schistosoma haematobium bladder infection Environmental Factors - Season/Climate: Present year-round; peak incidence in July-September rainy season, increased fly population, flooding ⭐ - Geography: Endemic in Indian subcontinent India, Pakistan, Bangladesh, Nepal, South-East Asia, Africa, Latin America; India: 2.30 million cases/year IDSP 2018; max cases from Uttar Pradesh - Socioeconomic: Unsafe water, open defecation, poor food hygiene, use of sewage-irrigated vegetables, low literacy, overcrowding Transmission Parameter Details ------ Mode Faecal-oral primary and urine-oral Routes 5 Fs Fluids contaminated water/ice, Food especially milk, shellfish, vegetables, Fingers hand contamination, Flies, Fomites No respiratory transmission S. typhi NOT excreted in sputum; NOT spread by droplet Portal of entry GI tract oral ingestion Incubation period Usually 10-14 days range 3-21 days depending on inoculum size ⭐ Period of communicability Throughout clinical illness and carrier state; convalescent carriers shed for 6-8 weeks; chronic carriers shed for years intermittently or continuously Descriptive Epidemiology - Global burden: 11-20 million cases/year; 128,000-161,000 deaths/year WHO; predominantly children of school age; highest incidence on Indian subcontinent 1000 cases/100,000 children in some areas - Indian scenario: Endemic; 2.30 million cases and 399 deaths in 2018 IDSP; notifiable disease; Typhoid Conjugate Vaccine TCV introduced in UIP 2021-22 - Epidemic pattern: Endemic with epidemic potential; point-source outbreaks contaminated water/food supply; sporadic cases from carriers; "Typhoid is an index of general sanitation of a country" Park ⭐ --- 2. CLINICAL FEATURES Stages of Disease - Classic 4-Week Pattern ⭐ Week Stage Features --------- Week 1 Prodromal / Incubation Gradual onset fever step-ladder pattern, headache, malaise, anorexia, dry cough, coated tongue, constipation children may have diarrhoea Week 2 Fastigium Stage of invasion Continuous high fever 39-40°C, relative bradycardia, Rose spots appear, splenomegaly, hepatomegaly, toxic appearance Week 3 Stage of maximum illness Fever sustained; complications appear perforation, bleeding; "muttering delirium / coma vigil"; patient picks at bedclothes Week 4 Defervescence / Convalescence Gradual resolution; fever decreases; recovery begins; relapse possible Cardinal / Pathognomonic Features ⭐ - Step-ladder pattern of fever - rises by 1°F each day, progressively to 103-104°F ⭐ - Relative bradycardia Faget's sign - pulse rate lower than expected for the degree of fever ⭐ - Rose spots Roseola typhosa - faint salmon-colored, blanching maculopapular rash on trunk/chest; appear at end of first week in 30% of cases ⭐ - Coated tongue "strawberry tongue" appearance at tip and edges - present in 51-56% - Splenomegaly - soft tender spleen in 2nd week - Hepatomegaly - common - Constipation adults or Diarrhoea children/paratyphoid - "Pea soup" stools - characteristic diarrhoea when it occurs - Muttering delirium / Coma vigil - neuropsychiatric symptom in severe disease ⭐ Clinical Types / Grades / Severity Type Features ------ Typical typhoid Classic 4-week illness with all features above Mild/ambulatory typhoid Subclinical or mild febrile illness; common in endemic areas with partial immunity Typhoid of infancy Vomiting, diarrhoea, convulsions; high mortality Complicated typhoid With intestinal perforation, haemorrhage, or neurological involvement Paratyphoid Caused by S. paratyphi A/B/C; shorter, milder course; similar clinical picture Carrier state Chronic asymptomatic carrier - most in gall bladder; 2-5% of cases --- 3. DIAGNOSIS Lab Investigations Investigation Details Timing --------- Blood culture 40-60% sensitivity; best in Week 1 bacteraemia peaks Week 1-2 ⭐ Bone marrow culture ⭐ GOLD STANDARD - 80% sensitivity; not reduced by prior antibiotics up to 5 days Any time Stool culture Positive in Week 3-4 when organism shed in bile back into gut Week 3-4 Urine culture Positive in Week 3-4 Week 3-4 String duodenal test Captures intestinal secretions; useful for carriers; combined with above gives 90% yield Any time Widal test Agglutination test - O titre ≥1:160 active disease; H titre ≥1:160 past infection/vaccination; NOT reliable as standalone - many false positives/negatives ⭐ Week 2 onwards Typhidot / TUBEX Rapid IgM/IgG detection; sensitivity 70-80%, specificity 80-90%; useful point-of-care Week 1-2 CBC Leucopenia + neutropenia 15-25% of cases ⭐; raised ESR; mild anaemia; thrombocytopenia in severe disease LFT Moderately raised transaminases; mild jaundice in hepatitis form Widal Test Interpretation ⭐ Titre Interpretation ------ O antigen ≥1:160 Active infection O titre is diagnostic H antigen ≥1:160 Past infection OR vaccination H titre persists Rising titre 4-fold Confirms active infection Vi antigen positive Carrier state 80% of chronic carriers Case Definition WHO / IDSP Definition Criteria ------ Suspected case Fever ≥38°C for ≥3 days + compatible clinical features headache, abdominal pain, rose spots Probable case Suspected case + positive Widal/Typhidot test Confirmed case ⭐ S. typhi or S. paratyphi isolated from blood/bone marrow/stool/urine culture Notifiable? YES - notifiable under IDSP; report to CMO --- 4. TREATMENT General / Supportive Care - Bed rest throughout febrile period - High-calorie, soft/liquid diet - easily digestible; avoid high-roughage foods risk of perforation - Adequate hydration - oral or IV - Antipyretics paracetamol preferred - avoid NSAIDs due to bleeding risk - Treat complications promptly - Steroids: Dexamethasone 3 mg/kg IV loading dose then 1 mg/kg every 6 hours x 8 doses - ONLY in severe disease with altered consciousness/shock ⭐ Specific Treatment ⭐ Current Antibiotic Recommendations Harrison's 2025: Indication Drug Dose Duration ------------ Empirical unknown susceptibility Ceftriaxone IV OR Azithromycin oral Ceftriaxone 2g/day IV; Azithromycin 1g day 1 then 500 mg OD 7-14 days Fully sensitive S. typhi Chloramphenicol OR Ampicillin OR Cotrimoxazole Chloramphenicol 25 mg/kg/day 14 days MDR S. typhi resistant to Chlor/Amp/Cotrim Ceftriaxone OR Azithromycin As above 7-10 days XDR S. typhi also resistant to FQ + 3rd gen cephalosporins Azithromycin 1g then 500 mg OD 7 days Decreased susceptibility to Ciprofloxacin DSC Avoid fluoroquinolones; use Azithromycin or Ceftriaxone Uncomplicated where FQ still sensitive Ciprofloxacin 500 mg BD 7-10 days ⭐ Note for India/PSM exams: Traditional teaching = Chloramphenicol was the original DOC; now Ceftriaxone or Azithromycin are preferred due to widespread MDR. Fluoroquinolones NO LONGER first-line on Indian subcontinent due to DSC strains. Carrier treatment: - Ampicillin/Amoxicillin 4-6g/day + Probenecid 2g/day x 6 weeks concentrated in bile - 70% clearance - Cholecystectomy + antibiotics for carriers with cholelithiasis ⭐ Isolation & Notification - Isolation type: Enteric precautions contact precautions for faeces/urine - Duration: Until 3 consecutive negative stool AND urine cultures on 3 separate days ⭐ - Notification: Mandatory to CMO under IDSP within 24 hours; all outbreaks to State + Centre --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ GI - Most common ⭐ Intestinal perforation 1% - Week 3-4; ileal Peyer's patches ulcerate; acute abdomen; requires emergency surgery + broad-spectrum antibiotics ⭐ GI - Second most common Intestinal haemorrhage 6% - Week 3-4; melaena or fresh blood PR; transfusion may be needed Hepatic Typhoid hepatitis, hepatomegaly, jaundice Splenic Splenic rupture rare but dramatic Neurological 2-40% Typhoid encephalopathy / Muttering delirium / Coma vigil ⭐; meningitis; Guillain-Barré syndrome; neuritis Cardiovascular Myocarditis; circulatory collapse; DIC Haematological Thrombocytopenia; DIC; haemolytic anaemia Respiratory Pneumonia; rarely pleuritis Renal Glomerulonephritis; HUS rare Relapse Up to 10% of cases; occurs 2-3 weeks after fever resolution; same strain ⭐ Carrier state 2-5% become chronic carriers gall bladder; associated with increased risk of gallbladder cancer ⭐ Complications of treatment Herxheimer-like reaction; antibiotic resistance ⭐ Most dangerous acute complication: Intestinal perforation mortality 10-32% CFR: 2.5% overall; 10-30% if untreated; 1% with prompt treatment --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Safe water supply: chlorination, boiling, filtration - Proper sanitation: use of latrines; ODF campaigns Swachh Bharat Mission - Hand-washing with soap before eating and after defecation - Food hygiene: avoid raw milk, unwashed vegetables, shellfish; cook food thoroughly - Fly control: proper garbage disposal, insecticides - Avoid street food in endemic areas - "Typhoid is a index of sanitation" - improve general living standards Primary Prevention - Specific Protection Immunization - Three Vaccines Available: Vaccine Type Efficacy Route Schedule Duration ------------------ TAB vaccine old, killed parenteral Killed whole-cell 70-90% short-term SC injection 2 doses 4 weeks apart + booster every 3 years 3 years; NOW largely REPLACED Vi polysaccharide vaccine Typherix/Typhim Vi Purified Vi capsular polysaccharide 60-80% IM/SC; single dose Single dose; booster every 3 years 3 years; for adults + children 2 yrs ⭐ Typhoid Conjugate Vaccine TCV - Typbar-TCV Vi polysaccharide conjugated to tetanus toxoid 80-85% IM; single dose India UIP: Single dose at 9-12 months introduced 2021-22 ⭐ Long-lasting; T-cell dependent immunity Ty21a Vivotif Live attenuated oral 67-80% Oral; 3-4 capsules alternate days Not in India UIP; used in travellers 5 years ⭐ Key exam fact: TCV Typhoid Conjugate Vaccine introduced into India's UIP as a single dose at 9-12 months - conjugation allows use in infants 2 years Vi polysaccharide alone is T-independent - ineffective 2 yrs Chemoprophylaxis: Not routinely recommended Secondary Prevention - Early diagnosis of cases - blood culture in all unexplained fever 3 days - Carrier detection: Vi antibody testing + stool culture for food handlers, water supply workers; duodenal drainage for biliary carrier confirmation - Carrier management: Treatment with amoxicillin/probenecid; restrict from food handling - Active case-finding during outbreaks - IDSP surveillance - alert on clusters of febrile illness - Widal screening in outbreak settings with limitations Tertiary Prevention - Rehabilitation - Nutritional rehabilitation post-illness recovery takes weeks to months - Monitoring for relapse 2-3 weeks post-defervescence - Follow-up stool and urine cultures at 3-4 months and 12 months to detect carrier state - Surgical follow-up for intestinal perforation cases - Cholecystectomy consideration for chronic gallbladder carriers Control Measures During an Outbreak - Case isolation: Enteric precautions until 3 negative stool/urine cultures - Contact tracing: Stool cultures of all household contacts; identify carrier - Source identification: Water/food/carrier - epidemic curve analysis - Water supply: Emergency chlorination; test water samples; boil-water advisory - Food handlers: Screen all; remove positive cases from food handling duties - Disinfection: Faeces/urine received in closed containers + 5% cresol for 2 hours ⭐; soiled linen in 2% chlorine + steam sterilization - Fly control: Insecticides, proper waste disposal during outbreak - Notification: CMO → State → Centre under IDSP - Outbreak vaccination: TCV/Vi vaccine to contacts and community National Programs & WHO Goals Program Details ------ Typhoid Conjugate Vaccine in UIP Single dose at 9-12 months; India phased rollout 2021-22 ⭐ Swachh Bharat Mission ODF India; launched 2 Oct 2014; most effective typhoid prevention at population level ⭐ Jal Jeevan Mission Safe piped water to all rural households IDSP Surveillance; typhoid is notifiable WHO target Promote TCV globally; integrate into childhood immunization schedules in endemic countries --- EXAM TIPS FOR TYPHOID FEVER Always Mention Key Facts ------ Incubation period 10-14 days range 3-21 days ⭐ Period of communicability Throughout illness + carrier state Notifiable YES - under IDSP Reservoir Human only no animal reservoir ⭐ Hallmark clinical features Step-ladder fever + relative bradycardia + rose spots ⭐ Week of complications Week 3-4 perforation, bleeding ⭐ Gold standard diagnosis Bone marrow culture 80% sensitivity ⭐ Best practical diagnosis Blood culture in Week 1 Widal interpretation O titre ≥1:160 = active disease; Vi = carrier Most dangerous complication Intestinal perforation ⭐ Drug of choice Ceftriaxone or Azithromycin MDR era ⭐ Isolation duration Until 3 negative stool + urine cultures ⭐ Carrier female example "Typhoid Mary" ⭐ Vaccine in India UIP TCV Typhoid Conjugate Vaccine - 9-12 months ⭐ National program Swachh Bharat Mission + TCV in UIP Carrier percentage 2-5% of cases become chronic carriers Carrier Vi antigen Positive in 80% of chronic carriers --- Ready for the next disease! Just name it. 😊 Q: Food poisoning A: Searching sources... A: I now have comprehensive data from Park's PSM textbook and Medical Microbiology. Here is your full proforma: --- FOOD POISONING Communicable Disease Epidemiology Proforma 3rd Year BSc / PSM Note for exam: Food poisoning is a syndrome caused by multiple agents. In PSM exams, questions usually ask you to compare types in a table or describe the most important types Staphylococcal, Salmonella, Botulism, Cl. perfringens, B. cereus. Always define it first, then cover each type systematically. --- 1. EPIDEMIOLOGY Definition ⭐ Food poisoning is an acute gastroenteritis caused by ingestion of food or drink contaminated with: - Living bacteria infective type - Their preformed toxins toxic/intoxication type - Inorganic chemicals, or poisons from plants/animals Diagnostic Triad Park's: 1. History of ingestion of a common food by a group 2. Attack of many persons at the same time 3. Similarity of signs and symptoms in the majority Classification of Food Poisoning A. Non-Bacterial: - Chemicals: arsenic, lead, mercury, cadmium, pesticides, fertilisers - Plant toxins: mushrooms, solanine green potatoes - Animal toxins: puffer fish tetrodotoxin, shellfish toxins B. Bacterial Most Important for Exams: Type Agent Mechanism --------- Toxic Intoxication Staph. aureus, Cl. botulinum, B. cereus emetic Preformed toxin in food ingested intradietetic toxin - NO bacterial multiplication in gut needed Infective Salmonella spp., ETEC, Vibrio Living bacteria ingested → multiply in gut → toxin produced in vivo Mixed Cl. perfringens, B. cereus diarrhoeal Bacteria ingested → sporulate/multiply → produce toxin in gut Agent Factors - Comparison Table ⭐ Feature Salmonella Staph. aureus Cl. botulinum Cl. perfringens B. cereus ------------------ Type Infective Toxic preformed Toxic preformed Mixed Mixed 2 types Agent S. typhimurium, S. enteritidis Coagulase +ve Staph. aureus enterotoxin Exotoxin types A, B, E Alpha toxin Emetic toxin / Diarrhoeal enterotoxin Incubation 12-24 hrs 1-8 hrs shortest! 18-36 hrs 6-24 hrs peak 10-14 hrs Emetic: 1-5 hrs; Diarrhoeal: 8-16 hrs Common food Meat, eggs, poultry, milk Custards, salads, milk, pastries, ham Home-canned veg, smoked fish, home-made cheese Meat dishes, poultry cooked and reheated Fried/boiled rice emetic; meat/vegetables diarrhoeal Fever YES chills, fever NO ⭐ NO NO/minimal NO Vomiting YES YES prominent Minimal Rare YES emetic type Diarrhoea YES watery YES NO/minimal YES YES diarrhoeal type Key feature Fever + gastroenteritis Vomiting prominent, NO fever, short IP Neurological symptoms ⭐ Diarrhoea + cramps, NO vomiting "Fried rice illness" emetic type Duration 2-3 days 24 hrs 4-8 days fatal 24 hrs 1 day 24 hrs Host Factors Parameter Details ------ Age group All ages; elderly, infants, immunocompromised at highest risk of severity Sex No significant difference Risk factors Improper food storage, mass/community feeding, banquets/weddings, food handler as carrier, immunocompromise Susceptibility Universal; gastric acidity is a partial protective barrier Environmental Factors - Season/Climate: Summer/hot months - bacterial growth favored by heat; inadequate refrigeration - Geography: Worldwide; higher burden in developing countries with poor food safety infrastructure; India - mass feeding events weddings, religious gatherings, school mid-day meals - Socioeconomic: Community feeding, prepared foods left at room temperature, poor kitchen hygiene, improper cold chain, flies, lack of handwashing Transmission Parameter Details ------ Mode Ingestion of contaminated food NOT person-to-person in most types Vehicle Specific foods for each type see table above Key characteristic Explosive point-source outbreak - many people affected simultaneously after a common meal ⭐ Portal of entry GI tract Incubation period Varies by agent 1-8 hrs = Staph; 18-36 hrs = Botulism; 12-24 hrs = Salmonella NOT communicable Food poisoning is NOT communicable person-to-person except Salmonella which can spread secondarily Descriptive Epidemiology - Global burden: Food-borne illness affects 600 million people/year globally WHO; 420,000 deaths/year; significant economic burden - Indian scenario: Major public health problem; school mid-day meal outbreaks Salmonella/Staph; notifiable under IDSP; mass gathering outbreaks common; FSSAI Food Safety and Standards Authority of India regulates food safety - Epidemic pattern: Explosive point-source outbreak - all cases occur within one incubation period; epidemic curve shows narrow, sharply peaked histogram ⭐ --- 2. CLINICAL FEATURES Stages of Disease Stage Features ------ Incubation period Very short 1-8 hrs for toxin types to 12-36 hrs for infective types Prodromal Usually absent - sudden onset Acute phase Nausea, vomiting, diarrhoea, abdominal cramps - vary by agent Convalescence Rapid recovery in most types except botulism; usually self-limiting Cardinal / Pathognomonic Features by Type ⭐ 1. Salmonella Food Poisoning Infective type - Sudden onset chills + fever + nausea + vomiting + profuse watery diarrhoea - Incubation 12-24 hours - Lasts 2-3 days; mortality 1% - Convalescent carrier state possible 2. Staphylococcal Food Poisoning Toxic type ⭐ - Shortest incubation: 1-8 hours preformed toxin - Sudden onset severe vomiting most prominent + abdominal cramps + watery diarrhoea - NO FEVER heat-stable, preformed toxin - not an infection ⭐ - Recovery within 24 hours - Food does NOT taste or appear spoiled - Source: food handler with skin infection OR asymptomatic nasal carrier 3. Botulism Toxic type ⭐ - MOST SERIOUS - Incubation 18-36 hours - NEUROLOGICAL symptoms predominate - NOT GI ⭐ - Diplopia, dysphagia, dysarthria, ptosis, blurring of vision, muscle weakness, quadriplegia - Descending flaccid paralysis cranial nerves first, then downward - NO fever; consciousness retained - GI symptoms minimal - Death from respiratory failure in 4-8 days ⭐ - Kills two-thirds of victims if untreated - Infant botulism - in vivo toxin production ingestion of spores, e.g., honey 4. Cl. perfringens Food Poisoning Mixed type - Incubation 6-24 hours peak 10-14 hrs - Diarrhoea + abdominal cramps; NO vomiting, NO fever ⭐ - Short duration 24 hours; NO deaths reported - Caused by reheated meat/poultry spores survive cooking, germinate during slow cooling 5. B. cereus Food Poisoning Two types ⭐ - Emetic type "Fried rice illness": IP 1-5 hrs; vomiting prominent; similar to Staph; caused by eating cooked rice left at room temperature - Diarrhoeal type: IP 8-16 hrs; diarrhoea + cramps; similar to Cl. perfringens Clinical Types / Grades Grade Features ------ Mild Self-limiting GI symptoms; no dehydration Moderate Significant vomiting/diarrhoea; some dehydration Severe Severe dehydration, electrolyte imbalance, shock Salmonella; respiratory paralysis Botulism --- 3. DIAGNOSIS Lab Investigations Investigation Details ------ Clinical diagnosis Explosive outbreak + common food + similar symptoms + short incubation period Stool examination Microscopy pus cells, RBCs; culture Salmonella Food culture Culture of implicated food - most important in outbreak investigation ⭐ Vomitus culture Staph. aureus coagulase-positive Food toxin testing ELISA for staphylococcal enterotoxin; mouse bioassay for botulinum toxin ⭐ Blood culture In Salmonella bacteraemia Stool for Cl. perfringens 10⁵ organisms/g in implicated food Serum botulinum toxin Mouse inoculation test - gold standard for botulism CBC Leucocytosis in infective type Salmonella; normal in toxic type Staph Electrolytes For dehydration assessment Case Definition WHO / IDSP Definition Criteria ------ Suspected outbreak ≥2 persons with similar illness after consuming a common food Confirmed case Isolation of pathogen from food/stool/blood OR detection of toxin Botulism suspected Descending paralysis after eating home-preserved food Notifiable? YES - all food poisoning outbreaks are notifiable under IDSP; report to CMO and Food Safety Officer FSSAI within 24 hours ⭐ --- 4. TREATMENT General / Supportive Care - Majority are self-limiting - supportive care is the cornerstone - Rehydration: ORS Plan A/B for mild-moderate dehydration; IV Ringer's Lactate for severe dehydration - Antipyretics for Salmonella with fever - Antiemetics metoclopramide/ondansetron for severe vomiting - Rest and NPO initially, then gradual oral refeeding - Monitor: Vitals, fluid balance, electrolytes Specific Treatment Agent Specific Treatment Notes --------- Salmonella Usually supportive; Ciprofloxacin or Azithromycin if severe/bacteraemic Antibiotics NOT needed for mild cases may prolong carrier state Staph. aureus Supportive only - antibiotics NOT indicated ⭐ Preformed toxin - antibiotics useless; rapid recovery Botulism ⭐ Trivalent botulinum antitoxin A, B, E 50,000-100,000 units IV + respiratory support ICU/ventilator Antitoxin only works BEFORE toxin binds to nerve; respiratory support may be needed for weeks Cl. perfringens Supportive only Self-limiting; no antibiotics needed B. cereus Supportive only Self-limiting; no antibiotics needed ⭐ Key exam point: Antibiotics are generally NOT indicated in food poisoning toxic types. Exception: severe Salmonella with bacteraemia or risk of systemic spread. Isolation & Notification - Isolation type: Enteric precautions contact precautions for stool - Duration: Until symptoms resolve - Notification: All outbreaks notified to CMO under IDSP within 24 hours; food safety violation reported to FSSAI ⭐ --- 5. COMPLICATIONS ⭐ System-wise Complications Type Complication ------ Immediate / Acute ⭐ Respiratory failure in Botulism MOST DANGEROUS - requires ventilator Fluid/Electrolyte Severe dehydration, hypovolaemic shock, hyponatraemia, hypokalaemia especially Salmonella Renal Acute kidney injury from dehydration Neurological Descending paralysis, cranial nerve palsies, diplopia Botulism ⭐ GI Intestinal perforation/bleeding rare, in Salmonella; toxic megacolon rare Haematological HUS Haemolytic Uraemic Syndrome from EHEC E. coli O157:H7 ⭐ Long-term Post-infectious IBS; Reactive arthritis after Salmonella; chronic carrier state Salmonella Mortality Botulism: 2/3 die if untreated ⭐; Salmonella: 1% CFR ⭐ Most dangerous form: Botulism - respiratory failure; kills 2/3 untreated ⭐ Most common form: Staphylococcal food poisoning equally common as Salmonella --- 6. PREVENTION AND CONTROL Most Scoring Section Primary Prevention - Health Promotion - Food safety education for food handlers, cooks, caterers ⭐ - Proper hand-washing before food preparation and after toilet - Personal hygiene: food handlers with skin infections/boils should NOT handle food Staph - Proper cooking: cook food to internal temperature ≥70°C kills vegetative bacteria - Safe storage: refrigerate at 5°C; hot food kept at 60°C danger zone: 5-60°C = bacterial growth zone - Avoid leaving cooked food at room temperature for 2 hours ⭐ - Avoid reheating rice/meat dishes Cl. perfringens, B. cereus - Proper hygiene in community feeding/mass catering Primary Prevention - Specific Protection No routine vaccines available for most food poisoning types Measure Details ------ Botulinum toxoid Available for laboratory workers and high-risk groups; NOT in general use Cold chain maintenance Refrigeration of perishable foods; cold chain for dairy/meat products Food irradiation WHO-approved method to kill pathogens in food Pasteurisation Kills Salmonella, Staph in milk and dairy products HACCP Hazard Analysis Critical Control Points - food industry standard ⭐ Food handler screening Stool cultures of food handlers in high-risk settings; nasal swabs for Staph carriage Antitoxin prophylaxis Botulinum antitoxin given to all persons who ate the implicated food in a botulism outbreak ⭐ Secondary Prevention - Rapid outbreak detection through IDSP alert system - Active case finding - identify all who ate the common meal - Food sample collection and testing within 48 hours of outbreak ⭐ - Withdrawal and destruction of implicated food - Epidemiological investigation: attack rate by food items cohort study; identify implicated food - Food handler investigation - culture stool/nasal swabs - Surveillance under IDSP and FSSAI Tertiary Prevention - Rehabilitation - Nutritional rehabilitation after illness - Renal support for AKI - Long-term respiratory rehabilitation and physiotherapy for botulism survivors - Neurological rehabilitation for botulism sequelae Control Measures During an Outbreak ⭐ - Immediate removal of suspected food from service; seal and refrigerate for testing - Case isolation: Enteric precautions; hospital admission for severe/botulism cases - Contact tracing: Identify all persons who ate the implicated food; observe for symptoms - Antitoxin distribution: In botulism outbreak - antitoxin to all who ate implicated food - Disinfection: Kitchen surfaces, utensils, food preparation area - Epidemiological investigation: - Line list of all cases - Attack rate by food item cohort study at the implicated event - Spot map if mass gathering - Identify critical control point failure improper storage? infected food handler? - Notification: CMO within 24 hrs → IDSP war room → FSSAI - Health education: Community + media communication to prevent panic and recurrence National Programs & WHO Goals Program Details ------ FSSAI Food Safety and Standards Authority of India Established under Food Safety and Standards Act, 2006 ⭐; regulates food safety, licensing, standards; key body for food poisoning prevention IDSP All food poisoning outbreaks notifiable; P-form + L-form surveillance SWACHH BHARAT MISSION Improved sanitation reduces food contamination WHO "Five Keys to Safer Food" ⭐ 1. Keep clean; 2. Separate raw and cooked; 3. Cook thoroughly; 4. Keep food at safe temperatures; 5. Use safe water and raw materials WHO Global Foodborne Disease Burden 600 million cases/year; 420,000 deaths; SDG 2 Zero Hunger and SDG 3 Good Health relevant --- EXAM TIPS FOR FOOD POISONING Always Mention Key Facts ------ Shortest incubation Staph. aureus: 1-8 hours ⭐ Longest incubation Botulism: 18-36 hours Most serious Botulism kills 2/3 untreated ⭐ Most common Staph. aureus and Salmonella equally common NO fever Staph. aureus, Botulism, Cl. perfringens ⭐ NO vomiting Cl. perfringens "diarrhoea only" ⭐ Neurological symptoms Botulism only ⭐ "Fried rice illness" B. cereus emetic type ⭐ Treatment for Botulism Trivalent antitoxin + ventilator ⭐ Antibiotics NOT indicated Staph, Cl. perfringens, B. cereus, mild Salmonella ⭐ Gold standard for botulism Mouse bioassay for toxin Notifiable YES - all outbreaks to CMO + FSSAI Key regulatory body FSSAI Food Safety and Standards Act, 2006 WHO Five Keys Keep clean; Separate raw/cooked; Cook thoroughly; Safe temperatures; Safe water Epidemic curve pattern Explosive point-source; narrow single peak ⭐ --- Ready for the next disease! Just name it. 😊
